TR201903490T4 - Füzyon proteini. - Google Patents

Füzyon proteini. Download PDF

Info

Publication number
TR201903490T4
TR201903490T4 TR2019/03490T TR201903490T TR201903490T4 TR 201903490 T4 TR201903490 T4 TR 201903490T4 TR 2019/03490 T TR2019/03490 T TR 2019/03490T TR 201903490 T TR201903490 T TR 201903490T TR 201903490 T4 TR201903490 T4 TR 201903490T4
Authority
TR
Turkey
Prior art keywords
fusion protein
nbp
p75ntr
fragment
pain
Prior art date
Application number
TR2019/03490T
Other languages
English (en)
Inventor
Westbrook Simon
Original Assignee
Levicept Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Levicept Ltd filed Critical Levicept Ltd
Publication of TR201903490T4 publication Critical patent/TR201903490T4/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2807—Headache; Migraine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2842—Pain, e.g. neuropathic pain, psychogenic pain

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)

Abstract

Mevcut buluş, p75NTR(NBP) parçasını ve bir immunoglobülin parçasını içeren bir p75NTR nörotrofin bağlayıcı protein (NBP)-Fc füzyon proteini ile ilgilidir. Belirli düzenlemelerde, p75NTR(NBP)-Fc füzyon proteini, ağrı ve/veya bir ağrı semptomunun tedavisinde kullanıma yöneliktir.
TR2019/03490T 2013-09-18 2014-09-18 Füzyon proteini. TR201903490T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1316592.3A GB201316592D0 (en) 2013-09-18 2013-09-18 Fusion protein

Publications (1)

Publication Number Publication Date
TR201903490T4 true TR201903490T4 (tr) 2019-03-21

Family

ID=49552839

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/03490T TR201903490T4 (tr) 2013-09-18 2014-09-18 Füzyon proteini.

Country Status (25)

Country Link
US (3) US9873728B2 (tr)
EP (1) EP3046934B1 (tr)
JP (3) JP6681834B2 (tr)
KR (1) KR102205633B1 (tr)
CN (1) CN105873943B (tr)
AU (1) AU2014322842B2 (tr)
CA (1) CA2924410C (tr)
CY (1) CY1121347T1 (tr)
DK (1) DK3046934T3 (tr)
EA (1) EA037416B1 (tr)
ES (1) ES2714694T3 (tr)
GB (1) GB201316592D0 (tr)
HR (1) HRP20190434T1 (tr)
HU (1) HUE043273T2 (tr)
IL (1) IL244588B (tr)
LT (1) LT3046934T (tr)
MX (1) MX2016003530A (tr)
NZ (1) NZ718044A (tr)
PL (1) PL3046934T3 (tr)
PT (1) PT3046934T (tr)
RS (1) RS58463B1 (tr)
SG (1) SG11201602068QA (tr)
SI (1) SI3046934T1 (tr)
TR (1) TR201903490T4 (tr)
WO (1) WO2015040398A1 (tr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ628685A (en) 2012-03-14 2017-12-22 Levicept Ltd Therapeutic use of p75ntr neurotrophin binding protein
GB201316592D0 (en) * 2013-09-18 2013-10-30 Levicept Ltd Fusion protein
GB201412748D0 (en) * 2014-07-17 2014-09-03 Levicept Ltd Therapeutic use of P75NTR neurotrophin binding protein
GB201504691D0 (en) * 2015-03-19 2015-05-06 Levicept Ltd Fusion protein
EP3711772A1 (en) 2019-03-20 2020-09-23 Oslo Universitetssykehus HF Recombinant proteins and fusion proteins
CN113456799A (zh) * 2020-12-25 2021-10-01 苏州澳宗生物科技有限公司 一种p75ECD在制备用于调节疼痛的药物中的应用
CN112851794B (zh) * 2021-02-04 2023-05-23 苏州铂维生物科技有限公司 一种基于cd271的抗原表位及其应用
US11608371B1 (en) * 2021-10-21 2023-03-21 Petmedix Ltd Therapeutic molecules
CA3236019A1 (en) * 2021-10-21 2023-04-27 Petmedix Ltd Proteins comprising the extracellular domain of p75ntr

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9022648D0 (en) 1990-10-18 1990-11-28 Charing Cross Sunley Research Polypeptide and its use
FR2686900B1 (fr) * 1992-01-31 1995-07-21 Rhone Poulenc Rorer Sa Nouveaux polypeptides ayant une activite de stimulation des colonies de granulocytes, leur preparation et compositions pharmaceutiques les contenant.
US7217798B2 (en) 2003-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of Fc-fusion protein serum half-lives by mutagenesis
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
JP2008528006A (ja) * 2005-01-28 2008-07-31 アポロ ライフ サイエンシズ リミテッド 分子およびそのキメラ分子
WO2007026567A1 (ja) 2005-08-30 2007-03-08 National University Corporation Chiba University ｐ７５ＮＴＲ阻害剤を有効成分として含有する鎮痛剤
US20070243132A1 (en) * 2005-12-22 2007-10-18 Apollo Life Sciences Limited Transdermal delivery of pharmaceutical agents
GB0717985D0 (en) * 2007-07-20 2007-10-24 Asterion Ltd Growth hormone fusion proteins
US8309088B2 (en) 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
US20100061981A1 (en) 2008-08-15 2010-03-11 The Salk Institute For Biological Studies p75NTR MEDIATES EPHRIN-A REVERSE SIGNALING
CA2787099A1 (en) * 2009-03-30 2010-10-14 Anice C. Lowen Influenza virus hemagglutinin polypeptides containing stem domains, vaccines and uses thereof
CA2777717C (en) * 2009-10-15 2021-05-25 Genentech, Inc. Chimeric fibroblast growth factors with altered receptor specificity
CN102770458A (zh) * 2009-12-02 2012-11-07 阿塞勒隆制药公司 用于增加Fc融合蛋白的血清半寿期的组合物和方法
CN102233128B (zh) 2010-11-26 2013-04-17 王延江 一种p75NTR-ECD在防治阿尔茨海默病药物中应用
ITRM20110024A1 (it) 2011-01-24 2012-07-25 Consiglio Nazionale Ricerche Uso di antagonisti del recettore p75ntr e/o di agonisti del recettore trka per il trattamento delle malattie infiammatorie croniche.
US20130078250A1 (en) * 2011-08-23 2013-03-28 Oliver Ast Bispecific t cell activating antigen binding molecules
TWI476001B (zh) * 2011-12-26 2015-03-11 Ind Tech Res Inst 三倍體Ｆｃ融合蛋白及其用途
CN102586313A (zh) 2012-03-05 2012-07-18 中国人民解放军第三军医大学野战外科研究所 p75NTR-ED-Fc融合蛋白的制备方法及其在损伤中枢神经再生与功能恢复中的应用
NZ628685A (en) * 2012-03-14 2017-12-22 Levicept Ltd Therapeutic use of p75ntr neurotrophin binding protein
EP2674439B1 (en) * 2012-06-13 2017-02-01 Rottapharm Biotech S.r.l. Anti-TrkA antibodies, derivatives and uses thereof
GB201316592D0 (en) * 2013-09-18 2013-10-30 Levicept Ltd Fusion protein
GB201412748D0 (en) 2014-07-17 2014-09-03 Levicept Ltd Therapeutic use of P75NTR neurotrophin binding protein
GB201504691D0 (en) 2015-03-19 2015-05-06 Levicept Ltd Fusion protein

Also Published As

Publication number Publication date
KR102205633B1 (ko) 2021-01-20
US10988526B2 (en) 2021-04-27
AU2014322842A1 (en) 2016-04-07
CA2924410A1 (en) 2015-03-26
BR112016006113A2 (pt) 2017-09-26
EP3046934A1 (en) 2016-07-27
PL3046934T3 (pl) 2019-05-31
EP3046934B1 (en) 2018-12-12
CN105873943B (zh) 2023-04-07
KR20160058872A (ko) 2016-05-25
AU2014322842B2 (en) 2018-08-16
JP7357088B2 (ja) 2023-10-05
WO2015040398A1 (en) 2015-03-26
JP2016531590A (ja) 2016-10-13
JP6681834B2 (ja) 2020-04-15
JP2022068253A (ja) 2022-05-09
IL244588B (en) 2019-12-31
DK3046934T3 (en) 2019-04-08
CA2924410C (en) 2023-01-24
HRP20190434T1 (hr) 2019-04-19
NZ718044A (en) 2020-07-31
US20180273603A1 (en) 2018-09-27
ES2714694T3 (es) 2019-05-29
PT3046934T (pt) 2019-03-25
SI3046934T1 (sl) 2019-04-30
HUE043273T2 (hu) 2019-08-28
US20160222082A1 (en) 2016-08-04
EA037416B1 (ru) 2021-03-25
JP2020062011A (ja) 2020-04-23
IL244588A0 (en) 2016-04-21
CN105873943A (zh) 2016-08-17
RS58463B1 (sr) 2019-04-30
US9873728B2 (en) 2018-01-23
MX2016003530A (es) 2016-10-13
GB201316592D0 (en) 2013-10-30
EA201690469A1 (ru) 2016-12-30
SG11201602068QA (en) 2016-04-28
LT3046934T (lt) 2019-03-25
US20210238256A1 (en) 2021-08-05
CY1121347T1 (el) 2020-05-29

Similar Documents

Publication Publication Date Title
TR201903490T4 (tr) Füzyon proteini.
CY1119213T1 (el) Πρωτεϊνη p75ntr συνδεσης νευροτροφινης για θεραπευτικη χρηση
CL2015003126A1 (es) Anticuerpos modificados de unión a fcrn humano y métodos de utilización.
BR112012013876A2 (pt) proteínas de ligação do antígeno humano que ligam o seu b-klotho, receptores de fgf e seus complexos
EA201591806A1 (ru) Лечение и профилактика острой почечной недостаточности с применением анти-альфа-v-бета-5 антител
EA201591785A1 (ru) Трициклические гетероциклы как ингибиторы белков бэт
EA201591331A1 (ru) Антагонисты il-33 и их применение
BR112016003394A2 (pt) usos de um antagonista de pd-1 e um agonista do gitr e de um anticorpo biespecífico ou fragmento de ligação do antígeno do mesmo, e, combinação farmacêutica
EA201600474A1 (ru) Комбинированная терапия с использованием антитела к ang2 и агониста cd40
DK3060237T3 (da) Modificeret omprogrammeringsprotein til anvendelse i behandling af cancer
CR20120105A (es) Proteínas terapéuticas de unión a dll4
BR112014011741A2 (pt) método de redução de dor nas articulações induzida pelo exercício em mamíferos não artríticos
EA201690898A1 (ru) Способы лечения таупатии
BR112016004324A2 (pt) anticorpos
EA201591762A1 (ru) Человеческие антитела к grem1
EA202090031A2 (ru) Человеческие антитела против gfr3 и способы их применения
EA202091315A3 (ru) Антитела человека, связывающиеся с g-белком rsv
TR201903840T4 (tr) İnsan tamamlayıcı C5'e bağlanan polipeptitler.
CY1124445T1 (el) Αντισωματα αντι-ccl17
EA201690992A1 (ru) Антитела, специфичные к fcrn
CL2015003174A1 (es) Anticuerpos anti-igf-1r con abolición de la unión al fcrn y su utilización en el tratamiento de enfermedades oculares vasculares
EA202090707A1 (ru) Эндоглиновые пептиды для лечения фиброзных заболеваний
CY1123519T1 (el) Ανθρωπινα μονοκλωνικα αντισωματα εξουδετερωσης il-ß
UA117933C2 (uk) Поліпептид, здатний зв'язувати с5-компонент комплементу людини
EA201792269A1 (ru) Полипептиды, нацеленные на слияние вич